Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission
Results from the Iceberg study
Bibliographic Data
| ID | 15519281 |
|---|---|
| Authors | Albino J Oliveira-Maia (0000-0001-5071-3007, Champalimaud Foundation), Benoît Rive (Janssen (France), corresponding author), Yordan Godinov, Siobhán Mulhern-Haughey (0000-0002-9708-4356, Janssen (Ireland)) |
| Year | 2024 |
| Volume | 15 |
| Pages | 1459633-1459633 |
| Publication date | 2024-10-07 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2024.1459633 |
| PMID | 39435126 |
| OpenAlex | W4403199683 |
| Language | EN |
| References cited | 4 |
For patients with TRD, esketamine NS had a significant functional benefit versus RWT after 6 months of treatment. Irrespective of treatment, achievement of clinical response or remission was insufficient to attain functional remission. Nevertheless, clinical remission increased the likelihood of achieving functional remission, further supporting an important role for clinical remission in for the path towards functional recovery
Anesthesia · Iceberg · Nasal administration · Nasal spray · Ginkgo biloba and Cashew Applications · Medicine · Olfactory and Sensory Function Studies · Treatment of Major Depression · Geology · Pharmacology
| Citation velocity | historical |
|---|---|
| Highly cited | No |